Bradford Bemiss, MD
Pulmonary Disease · Maywood, ILNPI 1033373709
Payments from drug & device makers
Across 359 payments — averaging $1765.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$246K
- Boehringer Ingelheim$241K
- E.r. Squibb & Sons, L.L.C.$70K
- GSK$46K
- Genentech, Inc.$30K
- AstraZeneca$347
- plus $764 from 14 others
Across 12 payments — averaging $114.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 117 | $245,949 |
| Boehringer Ingelheim | 180 | $241,039 |
| E.r. Squibb & Sons, L.L.C. | 4 | $69,713 |
| GSK | 14 | $46,281 |
| Genentech, Inc. | 8 | $29,813 |
| AstraZeneca | 5 | $347 |
| Insmed, Inc. | 10 | $162 |
| Melinta Therapeutics, LLC | 5 | $134 |
| Genentech USA, Inc. | 3 | $111 |
| Pulmonx Corporation | 1 | $62 |
| Regeneron Healthcare Solutions, Inc. | 2 | $43 |
| Liquidia Technologies, Inc. | 1 | $39 |
| La Jolla Pharmaceutical Company | 1 | $38 |
| Sandoz | 2 | $33 |
| Johnson & Johnson | 1 | $28 |
| Ipsen Biopharmaceuticals, Inc | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Sanofi | 1 | $24 |
| Baxter Healthcare | 1 | $21 |
| Merck | 1 | $17 |
How this compares
$633,906 in reported general payments places this provider in the 95th percentile of 539 pulmonary disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Maywood
- Marilyn GlassbergMaywood$1000K
- Matthew NobariMaywood$209K
- James GagermeierMaywood$109K
- Sana QuddusMaywood$54K
- Douglas HogarthChicago$3.1M
- Manu JainChicago$1.9M
- Momen WahidiChicago$1.2M
- Shashi BellamEvanston$1.2M
- Steven WhiteChicago$989K
- Ravi KalhanChicago$831K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.